REACH Study for Cystic Fibrosis Without Modulators
The REACH study is for people with Cystic Fibrosis (CF) who are not currently taking CFTR (cystic fibrosis transmembrane conductance regulator) modulators. This observational study aims to collect health information and samples from 400 participants to help researchers understand CF better and develop new treatments for those who can't use modulators. The study also wants to learn about how people with CF who don't take modulators get involved in research. Success in this study will be measured by changes in ppFEV1 (percent predicted forced expiratory volume in 1 second, a measure of lung function) over 12 months. The current recruitment status is unclear.
- Study design
- This is an observational study with a planned enrollment of 400 participants. It is a prospective, longitudinal study.
- What's involved
- You would need to provide written informed consent and be willing and able to follow the study visit schedule and other requirements.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months to measure changes in ppFEV1.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
At a glance
Conditions
Where it's being run
68 sites across 34 statesStudy leadership
- Deepika Polineni, MD, MPH · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
- Nicole Mayer-Hamblett, PhD · PRINCIPAL_INVESTIGATOR · Seattle Children's Hospital
- Scott Donaldson, MD · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill
- Felix Ratjen, MD · PRINCIPAL_INVESTIGATOR · University of Toronto
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in ppFEV1 at 12 months12 months
Mean change (standard deviation) in percent predicted forced expiratory volume in 1 second (ppFEV1) as measured by in-clinic spirometry from baseline to 12 months post-baseline.